As at Friday, the national figure of confirmed cases now stand at 3,912 while number of deaths increased to 117 with 679 persons already discharged.
NAFDAC had on March 20 approved the use of chloroquine for clinical trial treatment of the novel disease, warning however that the approval was not for the drug to be used as a treatment for the virus.The Director-General, NAFDAC, Prof Mojisola Adeyeye, had confirmed that only Lagos State,which has the highest number of cases and is the epicentre of the virus in the country, had signified interest in using the drug for a clinical trial to find treatment for the virus.
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
In an observational study of Hydroxychloroquine in hospitalized patients with Covid-19 in the U.S by a consortium of doctors
The research doctors examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City.
Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours. Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses.
In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed. (Funded by the National Institutes of Health.)